Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Enanta Pharmaceuticals Announces Poster Presentations at The Liver Meeting® 2019


Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that three preclinical posters on EDP-305, Enanta's lead Farnesoid X receptor (FXR) agonist, will be presented today at The Liver Meeting® 2019, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 8-12, 2019 in Boston.

EDP-305 poster presentations

Monday, November 11, 2019: 8:00 AM - 5:30 PM, Hynes Convention Center, Hall B

To learn more about the meeting, please visit https://www.aasld.org/event/liver-meeting

About EDP-305, a Farnesoid X Receptor (FXR) Agonist

EDP-305 is a potent Farnesoid X Receptor (FXR) agonist and Enanta's lead product candidate being developed for the treatment of NASH and PBC. FXR is a nuclear receptor and a main regulator of bile acid levels in the liver and small intestine. It responds to bile acids by regulating gene transcription of key enzymes and transporters, many of which play important roles in lipid metabolism, insulin resistance, inflammation, and fibrosis. EDP-305 represents a class of FXR agonists that has been designed to take advantage of increased binding interactions with the receptor. This non-bile acid class contains steroid and non-steroid components and does not contain the carboxylic acid group normally present in other classes of FXR agonists and natural bile acids that can lead to the formation of taurine and glycine conjugates.

About NAFLD, NASH, and FXR

Non-alcoholic fatty liver disease (NAFLD) is the accumulation of excessive fat in the form of triglycerides in patients' liver cells (steatosis) that is not caused by alcohol. NAFLD is widely considered to be the liver expression of metabolic disease associated with type 2 diabetes, insulin resistance, obesity, and hyperlipidemia. A subgroup of NAFLD patients also develops liver cell injury and inflammation. This condition is called non-alcoholic steatohepatitis (NASH). Patients with NASH can develop fibrosis (the first stage of scarring of the liver) and ultimately cirrhosis of the liver, potentially leading to hepatocellular carcinoma or requiring a liver transplant. Currently, there are no approved treatments for NASH.

About Enanta

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta's research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), and hepatitis B virus (HBV).

Enanta's research and development activities are funded by royalties from HCV products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is now sold by AbbVie in numerous countries as part of its newest treatment for chronic hepatitis C virus (HCV) infection. This leading HCV regimen is sold under the tradenames MAVYRETtm (U.S.) and MAVIRETtm (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.


These press releases may also interest you

at 23:08
Global premier mobile phone brand TECNO Mobile (www.TECNO-Mobile.com) announced its newest smart phone Pouvoir 4 as an early adopter of the operating system upgrading to Android 11 beta 1 starting from July 10th . As part of the Android 11 Developer...

at 23:05
Rigaku Corporation is pleased to announce the introduction of the new Rigaku ZSX Primus IVi tube-below sequential wavelength dispersive X-ray fluorescence (WDXRF) spectrometer. WDXRF analyzers are known for high sensitivity and spectral resolution,...

at 22:37
China Everbright Limited ("CEL"), and  Terminus Technologies (Terminus), recently announced the joint launch of "CEL AI Economy Fund", aiming to raise RMB 10 billion and operate in both Renminbi and US dollars. So far, the fund has received RMB 7...

at 22:25
Stats Perform, the SportsTech leader in data and AI technology, has extended its multi-year, exclusive official betting data and streaming partnership with Australia's rapidly growing Hungry Jack's National Basketball League (NBL). The combination...

at 22:01
Amgen  today announced an additional investment of approximately $421 million in BeiGene's registered direct offering of ordinary shares, which maintains Amgen's current pro rata ownership of BeiGene at approximately 20.3%.  This additional...

at 20:05
Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today the completion of study subjects enrollment in Phase I trial of...



News published on 11 november 2019 at 07:35 and distributed by: